Clinical trial participants who took tirzepatide, the drug sold as Zepbound, lost an average of 50 pounds (22.8 kilograms) ...

We recently published a list of 11 Best Performing Healthcare Stocks to Buy Now. In this article, we are going to take a look ...

It comes days after CVS Health's decision to drop Zepbound from some lists of medicines it covers for reimbursement, instead favoring Wegovy. Zepbound helped nearly 25% more participants lose more ...

Allison Stange lost 40 pounds since starting Zepbound in April 2024, improving both her blood pressure and sleep apnea. Now ...

Eli Lilly won’t lose its grip on the weight loss market despite recent investor concerns. Meanwhile, Zocdoc releases an ...

As Novo Nordisk works through a period of transition in the U.S. GLP-1 drug market, sales from the company's star obesity ...

What is the difference between Ozempic, Wegovy and Mounjaro? Curbs will have to be put on which patients are to be eligible for weight loss jabs Mounjaro and Wegovy when they are added to HSE ...

The FDA may begin enforcement actions against pharmacies compounding unauthorized semaglutide after May 22, 2025. Novo Nordisk has filed 111 lawsuits in 32 states to stop the sale of dangerous ...

A federal judge in Texas late Thursday rejected a bid by compounding pharmacies to keep making copies of Ozempic and Wegovy while a legal challenge over the shortage of those drugs unfolds.

The dominance of weight-loss drugs such as Ozempic and Wegovy have upended WeightWatchers business model, which was based around selling low-calorie foods and diet advice to overweight people.